AZD1775 continued access study to assess safety and tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies

Study identifier:D6014C00007

ClinicalTrials.gov identifier:NCT03313557

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open-label, Non-randomised, Multicentre Study to Allow Continued Access to and Assess the Safety and Tolerability of AZD1775 for Patients Enrolled in AZD1775 Clinical Pharmacology Studies

Medical condition

Solid Tumors

Phase

Phase 1

Healthy volunteers

Study drug

Wee-1 kinase inhibitor AZD1775

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 27 Oct 2017

Primary Completion Date: 17 May 2019

Study Completion Date: 17 May 2019

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2020 by AstraZeneca

Collaborators

Quintiles, Inc.

Inclusion and exclusion criteria

Inclusion Criteria

For inclusion in this study, patients must fulfil the following criteria:
• Has read and understands the informed consent form (ICF) and has given written
informed consent prior to any study procedures.
• Female or male aged ≥18 years.
• Has completed 1 of the parent AZD1775 clinical pharmacology studies (ie, D6014C00002, D6014C00003, D6014C00004, D6014C00005, or D6014C00006) and in the Investigator’s opinion will continue to benefit from treatment with AZD1775. Patients who discontinue early from the parent study will be considered by the Sponsor and treating physician on a case-by-case basis.
• Any prior radiation must have been completed at least 7 days prior to the start of study treatment, and patients must have recovered from any acute effects prior to the start of study treatment.
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 to 1.
• Baseline laboratory values within 7 days of study treatment initiation in the CA study:
- Absolute neutrophil count (ANC) ≥1500/μL.
- Haemoglobin ≥9 g/dL.
- Platelets ≥100,000/μL.
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 x upper limit of normal (ULN) or ≤5 x ULN if known hepatic metastases.
- Serum bilirubin within normal limits or ≤1.5 x ULN in patients with liver metastases; or total bilirubin ≤3.0 x ULN with direct bilirubin within normal limits in patients with well documented Gilbert’s Syndrome.
- Serum creatinine ≤1.5 x ULN, or measured creatinine clearance (CrCl) calculated by Cockcroft-Gault method ≥45 mL/min (confirmation of creatinine clearance is only required when creatinine is >1.5 x ULN) CrCl (glomerular filtration rate) = (140-age) x (weight/kg) x Fa (72 x serum creatinine mg/dL)
where F = 0.85 for females and F = 1 for males.
• Female patients who are of non-childbearing potential and fertile women of childbearing potential (WoCBP) who agree to use adequate contraceptive measures that are in place during screening (or consent), for the duration of the study, and for 1 month after treatment stops; who are not breastfeeding; and who have a negative serum or urine pregnancy test prior to the start of study treatment.
• Male patients must be willing to use barrier contraception (ie, condoms) for the duration of the study and for 3 months after study treatment discontinuation.
• Willingness and ability to comply with the study and the follow-up procedures.

Exclusion Criteria

Patients must not enrol in this study if any of the following exclusion criteria are fulfilled:
• Involvement in the planning and/or conduct of the study (applies to both AstraZeneca personnel and/or personnel at the study centre).
• Previous enrolment and received study treatment in the present study. Patients can, however, be re-screened if the reason for the screen failure no longer exists.
• Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study.
• Must not have received another systemic anti-cancer therapy in the interval following participation in the AZD1775 clinical pharmacology study and the start of treatment on the CA protocol.
• Not developed any clinical findings suggestive of brain metastasis. Patients continue to be neurological stable and remain off systemic corticosteroids following treatment of known brain metastases.
• Did not tolerate AZD1775 in the parent study in the opinion of the Investigator.
• Where a course of palliative radiotherapy was indicated, the last fraction must have been delivered before the start of study treatment on the CA study.
• Major surgical procedures ≤28 days of beginning study treatment, or minor surgical
procedures ≤7 days. No waiting period required following port-a-cath placement or other central venous access placement.
• Grade >1 toxicities from prior therapy, according to the Common Terminology Criteria for Adverse Events (CTCAE), excluding alopecia or anorexia.
• Continue to be able to swallow oral medication, did not undergo placement of a percutaneous endoscopic gastrostomy tube and did not require total parenteral nutrition.
• Has had prescription or non-prescription drugs or other products known to be sensitive to CYP3A4 substrates or CYP3A4 substrates with a narrow therapeutic index, or to be moderate to strong inhibitors/inducers of CYP3A4 between the
parent study and entry into this CA study. Co administration of aprepitant or fosaprepitant during this study is prohibited.
• Has consumed herbal preparations between the parent study and entry into this CA study.
• Has consumed grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade, or other products containing grapefruit or Seville oranges between the parent study and entry into the CA study.
• Any known hypersensitivity or contraindication to AZD1775 or to the components thereof.
• Any of the following cardiac diseases currently or within the last 6 months as defined by the New York Heart Association ≥Class 2:
- Unstable angina pectoris.
- Congestive heart failure.
- Acute myocardial infarction.
- Conduction abnormality not controlled with pacemaker or medication.
- Significant ventricular or supraventricular arrhythmias (patients with chronic rate-controlled atrial fibrillation in the absence of other cardiac
abnormalities are eligible).
• AZD1775 should not be given to patients who have a history of Torsades de pointes unless all risk factors that contributed to Torsades have been corrected. AZD1775 has not been studied in patients with ventricular arrhythmias or recent myocardial
infarction.
• Patient with mean resting QTc interval (specifically QTc calculated using the
Fridericia formula [QTcF]) >450 ms for males and >470 ms for females from 3 electrocardiograms (ECGs) performed within 2 to 5 minutes apart during
screening, or congenital long QT syndrome.
• Pregnant or lactating female patients.
• Serious, symptomatic active infection at the time of study entry, or another serious underlying medical condition that would impair the ability of the patient to receive study treatment.
• Active infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).

No locations available

Arms	Assigned Interventions
Experimental: Wee-1 kinase inhibitor AZD1775 To assess the safety of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in patients who have previously completed 1 of the AZD1775 clinical pharmacology studies and not have met any requirements to permanently discontinue treatment with AZD1775.	Drug: Wee-1 kinase inhibitor AZD1775 Patients will receive AZD1775 300 mg orally once daily. Days 1 to 5 and 8 to 12 of a 21 day cycle (ie, 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle). All patients must receive a serotonin receptor 3 (5-HT3) antagonist, ondansetron (Zofran) 8 mg orally/IV or granisetron (Kytril) 1 mg orally/IV prior to each dose of AZD1775. Dexamethasone 4 mg orally/IV will be given with each AZD1775 dose at a minimum on the first day of dosing of AZD1775 of every 5 day dosing period, unless contraindicated or not well-tolerated. Other Name: N/A

Arms

Assigned Interventions

Experimental: Wee-1 kinase inhibitor AZD1775
To assess the safety of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in patients who have previously completed 1 of the AZD1775 clinical pharmacology studies and not have met any requirements to permanently discontinue treatment with AZD1775.

Drug: Wee-1 kinase inhibitor AZD1775
Patients will receive AZD1775 300 mg orally once daily. Days 1 to 5 and 8 to 12 of a 21 day cycle (ie, 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle). All patients must receive a serotonin receptor 3 (5-HT3) antagonist, ondansetron (Zofran) 8 mg orally/IV or granisetron (Kytril) 1 mg orally/IV prior to each dose of AZD1775. Dexamethasone 4 mg orally/IV will be given with each AZD1775 dose at a minimum on the first day of dosing of AZD1775 of every 5 day dosing period, unless contraindicated or not well-tolerated.

Other Name: N/A

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]

Investigators

Principal Investigator

Lone Ottesen

AstraZeneca